Mechanism of estrogen-induced apoptosis in breast cancer cells: Role of the NF-κB signaling pathway
- 129 Downloads
The ability of sex steroid hormones to up-regulate the apoptotic signaling proteins is well documented; however, the apoptotic potential of sex hormones is not remarkable and fully compensated by their growth stimulatory action to target cells. In the present study using the long-term cultivation of estrogen-dependent MCF-7 breast cancer cells in steroid-free medium, we have established a cell subline, designed as MCF-7/LS, which was characterized by the resistance to growth stimulatory estradiol action and hypersensitivity to estrogen-induced apoptosis. We have demonstrated that estrogen treatment of the cells does not influence on the level of TNF-R1 or Fas, but dramatically decreases the transcriptional activity of NF-κB. Importantly, the MCF-7/LS cells, which are insensitive to growth stimulatory estrogen action, retain the ability to decrease in the NF-κB activity in response to estrogen stimulus. Furthermore, the significant increase in the basal (in the absence of ligand) estrogen receptor (ER)-dependent transcriptional activity in the MCF-7/LS cells was revealed and reciprocal transcriptional antagonism between ER and NF-κB was demonstrated. Finally, we proved the possible involvement of phosphatidylinositol-3 kinase (PI3K) in the ligand-independent ER activation. In general, the results presented suggest that long-term growth of MCF-7 breast cancer cells in steroid-free medium is accompanied with the increase in the basal ER-dependent transcriptional activity as well as the maintenance of the negative regulatory loop ER-NF-κB. The latter may be considered as one of the factors resulting in a disbalance between pro-and anti-apoptotic pathways and enhancement in estrogen apoptotic action in the cells.
Key wordsbreast cancer apoptosis estrogens NF-κB phosphatidylinositol-3 kinase
estrogen responsive element
phosphatase dephosphorylating 3-OH-phosphoinositides
tumor necrosis factor α
type I tumor necrosis factor receptor
Unable to display preview. Download preview PDF.
- 2.Bershtein, L. M., and Santen, R. (2002) Vopr. Onkol., 48, 17–23.Google Scholar
- 24.Osipo, C., Liu, H., Meeke, K., and Jordan, V. C. (2004) Exp. Biol. Med. (Maywood), 229, 722–731.Google Scholar
- 25.Okumura, N., Saji, S., Eguchi, H., Hayashi, S., Saji, S., and Nakashima, S. (2002) Jap. J. Cancer Res., 93, 867–873.Google Scholar
- 26.Saji, S., Nakashima, S., Hayashi, S., Toi, M., Saji, S., and Nozawa, Y. (1999) Jap. J. Cancer Res., 90, 210–218.Google Scholar
- 38.Biswas, D. K., Singh, S., Shi, Q., Pardee, A. B., and Iglehart, J. D. (2005) Sci. STKE, 288, 27–32.Google Scholar